Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

This study has been completed.
Information provided by:
Eli Lilly and Company Identifier:
First received: January 6, 2005
Last updated: January 24, 2007
Last verified: January 2007